HOME >> MEDICINE >> NEWS
Adams Respiratory Therapeutics and Hollister-Stier Laboratories to co-promote ALLERx(TM) dose pack

Chester, New Jersey April 5th, 2004 Adams Respiratory Therapeutics has formed an alliance with Hollister-Stier Laboratories LLC to promote Adams' ALLERxTM Dose Pack, a day/night treatment regimen for symptoms associated with allergic rhinitis, non-allergic rhinitis, vasomotor rhinitis and the common cold.

With the HollisterStier team calling on over 3,000 Allergists and Otolaryngologists nationally and Adams continuing to focus on Primary Care physicians, this alliance is designed to greatly heighten awareness of ALLERxTM Dose Pack as an important treatment option.

"We're excited to be working in concert with HollisterStier," remarked Mike Valentino, President and CEO of Adams Respiratory Therapeutics. "This co-promotion will expose additional physicians to the unique profile and benefits of ALLERxTM Dose Pack. HollisterStier's longstanding rapport with these important physician segments will be a key element in making this a successful venture."

"Having a product with the unique attributes of ALLERxTM Dose Pack will certainly strengthen our portfolio and create a real marketing opportunity for both parties," agreed Anthony D. Bonanzino, Ph.D., President & CEO of HollisterStier.

Located in Spokane, Washington, HollisterStier is a worldwide leader in the manufacture of allergenic extracts, targeted primarily at treating allergy and asthma. Their customer base includes over 3,000 Allergists/Immunologists and Otolaryngologists that specialize in allergic disease. HollisterStier enjoys a longstanding, close franchise with this group of specialists. In addition to its Allergy Business, HollisterStier is a nationally recognized contract manufacturer of sterile injectable vials, syringes and lyophilized products for the pharmaceutical and biopharmaceutical industries.

Headquartered in Chester, New Jersey, Adams Respiratory Therapeutics develops, markets and sells prescription and non-p
'"/>


5-Apr-2004


Page: 1 2

Related medicine news :

1. Respiratory infections, not air pollution, pose winter health threat for children with asthma
2. Respiratory therapists twice as likely to have asthma than other therapists
3. Respiratory health endowment to coordinate public education about asthma
4. Antibiotic Prophylaxis Could Help Prevent Respiratory Infections in the Critically Ill
5. 2005 Pharmacology, Therapeutics, & Toxicology Research Award
6. 2004 Pharmacology/Therapeutics/Toxicology Award to Haas

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult with gluten intolerance ... you may be interested in participating in a research study that focuses on family ... understand more about the relational aspects of adults who have gluten sensitivities who cohabitate ...
(Date:8/19/2017)... York (PRWEB) , ... August 19, 2017 , ... ... has announced that it is the first organization with pending recognition status from ... Diabetes Prevention Program (“DPP”) via group telehealth classes and live video conferencing. ...
(Date:8/19/2017)... Fla. (PRWEB) , ... August 19, 2017 , ... ... Taufiq Ahmed, M.D., has joined its Orlando location as an interventional pain management ... anesthesiology, a focus on the treatment of migraine headaches, and significant experience in ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... specialized asset-light logistics provider of complex transport solutions for mission-critical and non-discretionary ... Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: RRTS). ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance ... a new charity drive to generate community support for efforts to educate the local ... and treatments for all types of cancer. , Each day in America, roughly ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
Breaking Medicine Technology:
Cached News: